ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $0.74, $0.03 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $36.6 million versus the consensus estimate of $39.63 million.

• Net revenues of $36.6 million, an increase of 78% as compared to the same period in 2016
• GAAP net income of $1.2 million and diluted GAAP earnings per share of $0.10
• Adjusted non-GAAP EBITDA of $14.7 million
• Adjusted non-GAAP diluted earnings per share of $0.74

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.